The ICMR national task force for Covid-19 has decided to include Molnupiravir antivirus drugs in the clinical management protocol for Covid at that time, the official source said on Tuesday.
Experts The task force quoted security issues and argued that Molnupiravir was not many benefits in Covid treatment to arrive at the decision in the meeting held on Monday.
“Members of the National Task Force for Covid do not support including drugs in national medicine guidelines quoting that it does not have many benefits in the treatment of koronavirus infection and that there is a security problem,” an official source.
The Head of the Indian Medical Research Council (ICMR) Dr.
Balram Bhargava has last week said that Molnupiravir has a major safety problem.
He added that who and England have not put it for treatment.
“We must remember that this drug has the main safety problem,” he said, added, it could cause defects in the developing fetus and can damage the muscles too.
“Contraception must be made for three months …
if this drug is given,” he said.
Molnupiravir is not many benefits, will not save it in the protocol, the ICMR task unit said
